Results 241 to 250 of about 620,845 (342)

Phenotyping patients with chronic obstructive pulmonary disease and heart failure

ESC Heart Failure, Volume 12, Issue 2, Page 900-911, April 2025.
Central illustration. Abbreviations: ACEi, angiotensin‐converting enzyme inhibitor; ARB, angiotensin receptor blocker; ARNi, angiotensin‐receptor‐neprilysin inhibitor; CI, confidence interval; COPD, chronic obstructive pulmonary disease; CRT, cardiac resynchronization therapy; CV, cardiovascular; EF, ejection fraction; eGFR, estimated glomerular ...
Peter Moritz Becher, Felix Lindberg, Lina Benson, Camilla Hage, Ulf Dahlström, Stephan Rosenkranz, Francesco Cosentino, Giuseppe M.C. Rosano, Stefan Blankenberg, Paulus Kirchhof, Frieder Braunschweig, Lars H. Lund, Gianluigi Savarese   +12 more
wiley   +1 more source

Predicting acute decompensated heart failure using circadian markers from heart rate time series

ESC Heart Failure, EarlyView.
Circadian metrics—amplitude, mesor, and acrophase—derived from a wrist‐worn heart rate monitor can predict acute decompensated heart failure (ADHF) up to 21 days before onset. In 65 post‐ADHF patients, an LSTM model achieved 74% sensitivity, and 73% specificity trained on 21‐day sequences. These findings support circadian rhythm analysis as a promising
Valerie A. A. van Es, Mayke M. C. J. van Leunen, Ignace L. J. de Lathauwer, Cindy C. A. G. Verstappen, René A. Tio, Ruud F. Spee, Lu Yuan, Monica Betta, Giacomo Handjaras, Hareld M. C. Kemps   +9 more
wiley   +1 more source

Digital implementation strategy to increase SGLT2 inhibitor uptake in heart failure: Study design of EMAIL‐HF

ESC Heart Failure, EarlyView.
Abstract Aims The EMAIL‐HF trial aims to evaluate whether a digital guideline implementation strategy can increase and accelerate initiation of sodium‐glucose co‐transporter 2 (SGLT2) inhibitors in patients with heart failure (HF). Methods and results EMAIL‐HF is a pragmatic, registry‐based, randomized controlled trial including patients with a ...
Mariam Elmegaard, Lars Køber, Mads Kristian Ersbøll, Theis Lange, Christian Ditlev Tuxen, Mette Rauhe Mouridsen, Trine Kiilerich Lauridsen, Jens Jakob Thune, Peter Godsk Jørgensen, Morten Lamberts, Nadia Paarup Dridi, Peter Bonfils, Morten Petersen, Nis Ottesen Stride, Anders Barasa, Jesper Jensen, Caroline Garred, Emil Fosbøl, Emil Wolsk, John McMurray, Mark Petrie, Morten Schou   +21 more
wiley   +1 more source

Cardiac rehabilitation and health‐related quality of life in preserved ejection fraction heart failure: A meta‐analysis

ESC Heart Failure, EarlyView.
Abstract Aims The study aims to evaluate the effects of exercise‐based cardiac rehabilitation (ExCR) on the health‐related quality of life (HRQoL) in people with heart failure preserved ejection fraction (HFpEF). Methods This study is a systematic review and meta‐analysis.
Chenyao Ding, Yawen Gao, Rod S. Taylor
wiley   +1 more source

Cardiometabolic outcomes with dapagliflozin after myocardial infarction by baseline ejection fraction: DAPA‐MI

ESC Heart Failure, EarlyView.
We investigated cardiometabolic outcomes in patients treated with dapagliflozin 10 mg once daily or placebo after acute myocardial infarction according to LVEF at randomisation in the registry‐based, randomised DAPA‐MI trial. Regardless of baseline LVEF, dapagliflozin resulted in significant cardiometabolic benefits versus placebo, suggesting that ...
David Erlinge, Stefan James, John Deanfield, Niclas Eriksson, Mark de Belder, Monér Alchay, David Austin, Daniel A. Jones, Annica Ravn‐Fischer, Sofia Sederholm Lawesson, Nikunj Shah, Julian W. Strange, Karolina Szummer, Wilhelm Ridderstråle, Ehsan Parvaresh Rizi, Anna Maria Langkilde, Peter A. Johansson, Darren K. McGuire, Jonas Oldgren, Robert F. Storey   +19 more
wiley   +1 more source

Soluble urokinase plasminogen activator receptor and outcomes in HFpEF: A TOPCAT ancillary study

ESC Heart Failure, EarlyView.
Abstract Aims Inflammation is postulated to be a key pathogenic mechanism in heart failure with preserved ejection fraction (HFpEF). Soluble urokinase plasminogen activator receptor (suPAR), a regulator of innate immune activity, is associated with incident heart failure; however, its role in HFpEF remains unclear.
Christina G. Hutten, Annika Tekumulla, Anis Ismail, Alexi Vasbinder, Theresa Farhat, Pennelope Kunkle, Sascha N. Goonewardena, Ahmed Abdel‐Latif, Bertram Pitt, Salim S. Hayek   +9 more
wiley   +1 more source

Mapping of current practices of palliative care for patients with heart failure throughout Europe: A scoping review

ESC Heart Failure, EarlyView.
Abstract Heart failure (HF) is a growing health and societal challenge in Europe, due to an increasingly elderly, frail and multimorbid population. Many patients with HF experience a high burden of complex and multidimensional symptoms leading to a reduced quality of life and significant socioeconomic impact. Despite proven benefits, the integration of
Tania Pastrana, Matthew Grant, Paula Hidalgo Andrade, Daniele Marelli, Klaus Witte, Geert‐Jan Geersing, Carla Ripamonti, Roman Rolke, Marco Metra, Matteo Pagnesi, Everlien De Graaf, Cosimo Chelazzi, on behalf of the RAPHAEL consortium   +12 more
wiley   +1 more source

A heart failure network model to improve outcome and trans‐sectoral guideline‐directed medical treatment utilization

ESC Heart Failure, EarlyView.
Abstract Aims Heart failure (HF) is a major cause of hospitalization, mortality and healthcare costs. Reducing its socioeconomic burden is a key global public health priority. HF networks are recommended to improve screening and management of HF patients.
Christina Paitazoglou, Dominik Jurczyk, Matthias Mezger, Felicitas Lemmer, Bernhard Schwaab, Patricia Grube, Thomas Helms, Bettina Zippel‐Schultz, Buntaro Fujita, Roland Tilz, Thomas Stiermaier, Christian Frerker, Stephan Ensminger, Ingo Eitel   +13 more
wiley   +1 more source

Cardiac resynchronization therapy for enabling guideline‐directed medical therapy optimization in heart failure

European Journal of Heart Failure, EarlyView.
Cardiac resynchronization therapy (CRT) as an enabler for guideline‐directed medical therapy (GDMT) in the Swedish Heart Failure Registry (SwedeHF). The figure summarizes the selection of the study population, changes in GDMTs and loop diuretic use/doses from baseline to 1.5‐year follow‐up in patients receiving versus not receiving CRT, and reports the
Daniela Tomasoni, Lina Benson, Paolo Gatti, Alessandro Villaschi, Charlotta Ljungman, Marco Metra, Raffaele Scorza, Frieder Braunschweig, Michael Melin, Giuseppe Rosano, Michael Böhm, Javed Butler, William T. Abraham, Wilfried Mullens, Fredrik Gadler, Cecilia Linde, Lars H. Lund, Gianluigi Savarese   +17 more
wiley   +1 more source

Missed care or missed opportunities in general practice nursing [PDF]

Claire Verrall, Eileen Willis, Alexander Gerrie, James N. Thompson   +3 more
openalex   +1 more source